Genelux Corporation to Participate in a Fireside Chat With H.C. Wainwright
Genelux Corporation to Participate in a Fireside Chat With H.C. Wainwright
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.
加州西湖村，2024年12月13日 (全球新聞通訊) -- Genelux Corporation (納斯達克: GNLX)，一家處於晚期臨牀階段的免疫腫瘤學公司，今天宣佈，董事會主席兼首席執行官托馬斯·辛德里克將於2024年12月16日參加與H.C. Wainwright & Co.的虛擬爐邊聊天。
Biotech Equity Research Analyst, Emily Bodnar, will moderate the HCW@Home session which is scheduled to begin at 11:00 a.m. ET. The discussion will focus on the company's clinical program of its lead candidate, Olvi-Vec, including its ongoing Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC), Phase 1b/2 trial in small-cell lung cancer (SCLC) and Phase 2 trial in non-small cell lung cancer (NSCLC). To join, please register at . An archived replay will be available for approximately 90 days following the event on the company's IR page.
生物技術股票研究分析師艾米莉·博德納將主持定於上午11:00（東部時間）開始的HCW@Home會議。討論將集中在公司的主導候選藥物Olvi-Vec的臨牀項目上，包括其正在進行的鉑耐藥/難治性卵巢癌（PRROC）的3期註冊試驗、小細胞肺癌（SCLC）的1b/2期試驗以及非小細胞肺癌（NSCLC）的2期試驗。要加入，請註冊。活動結束後，檔案重播將在公司的投資者關係頁面上提供，持續大約90天。
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit and follow us on Twitter @Genelux_Corp and on LinkedIn.
關於Genelux Corporation
Genelux是一家處於晚期臨牀階段的生物製藥公司，專注於開發針對患有侵襲性和/或難治性實體瘤的患者的下一代溶瘤免疫療法。公司的最先進產品候選藥物Olvi-Vec（olvimulogene nanivacirepvec）是一種專有的、改造的牛痘病毒株。Olvi-Vec目前正在OnPrime/GOG-3076中接受評估，這是一個多中心、隨機、開放標籤的3期註冊試驗，評估Olvi-Vec與鉑基雙藥+貝伐單抗聯合治療與醫生選擇化療和貝伐單抗在鉑耐藥/難治性卵巢癌患者中的療效和安全性。Genelux的發現和開發工作的核心圍繞其專有的CHOICE平台，該平台使得公司開發出豐富的隔離和工程改造的溶瘤牛痘病毒免疫治療產品候選藥物，包括Olvi-Vec。有關更多信息，請訪問並在Twitter上關注我們 @Genelux_CORP 和LinkedIn。
Investor and Media Contacts
投資者和媒體聯繫人
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
安基特·巴爾加瓦，醫學博士
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
來源：Genelux公司
Source: Genelux Corporation
來源：Genelux公司
譯文內容由第三人軟體翻譯。
